Daily Newsletter

08 September 2023

Daily Newsletter

08 September 2023

Cidara gets a nod from Janssen to continue CD388 flu prevention programme

Cidara will also receive $7m in milestone payments for the drug-Fc conjugate as part of the Election to Proceed from Janssen.

Phalguni Deswal September 07 2023

Janssen Pharmaceuticals has given Cidara Therapeutics an Election to Proceed Notice for the continued development of CD388 for the prevention of influenza A and B.

The news comes within the required 90-day period that allows Janssen to retain the development and commercialisation rights for CD388. In July, Cidara announced that its partnership with Janssen was still in effect despite the latter's plans to discontinue the development of JNJ-0953 (CD388).

CD388 is a drug-Fc conjugate (DFCs) immunotherapy developed using Cidara’s proprietary Cloudbreak platform. Cidara states that CD388 is not a vaccine but acts by inhibiting viral proliferation and allowing for immune-mediated viral clearance, which, as per the company, provides an advantage over current flu vaccines.

The announcement led to an 18% increase in Cidara’s stock price at market open on 6 September, compared to market close on the previous day.

Despite retaining ownership of CD388, Janssen is not planning to add the drug to its portfolio, but rather transfer CD388’s rights and obligations to a third party.

The Election to Proceed also unlocks $7m in milestone payments for Cidara. The US-based company is also in line to receive up to $685m in milestone-based payments and royalties from the CD388 influenza programme.

CD388 received a fast track designation by the US Food and Drug Administration (FDA) in June. It is currently being investigated in two Phase I studies (NCT05285137 and NCT05619536) and one Phase IIa (NCT05523089) trial, with all the trial costs being reimbursed by Janssen.

The interim analysis of the Phase IIa data showed a decrease in influenza virus replication with a single dose of CD388. Additionally, the CD388 treatment group reported lower influenza incidence rates, compared to the placebo arm.

There were no treatment-associated adverse events or trial discontinuations. Cidara expects to deliver complete Phase IIa data to Janssen by the end of 2023.

The development of influenza vaccines has seen an uptick in recent years, with two vaccine candidates currently in Phase II clinical development. Osivax’s OVX836 is currently being evaluated in combination with quadrivalent influenza vaccines (QIVs) in a Phase IIa study (NCT05734040). Imutex’s Flu-v, T-cell vaccine is being evaluated for preventing H1N1, and influenza A and B.

M&A in the Contract Manufacturing Industry

Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close